CLINICAL_TRIALS
trial_result
· 2015-03-31
Clinical Trial Update: Dosing Study of Replagal in Patients With Fabry Disease [Phase 2]
Summary
This clinical trial update reports a Phase 2 dosing study of Replagal (agalsidase alfa) in patients with Fabry disease, with results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Baylor Research Institute | Conditions: Fabry Disease | Phase 2 | Status: COMPLETED | Results posted: 2015-03-31